Abstract 3779
Background
HER2-gene mutations are considered to be an important prognostic factor in patients with lung cancer. The aim of our study was to assess the frequency and significance of HER2-gene single nucleotide polymorphisms -1985G>T and P1170AC>G among the patients with small-cell and non-small cell lung cancer and to compare this data to healthy subjects.
Methods
The study was performed among 359 patients (69% males and 31% females; mean age of 59.96 ± 18.24 years) with diagnosis of stage IV small-cell (24.6% of patients) and non-small cell lung cancer (75.4% of patients) compared to 167 healthy subjects (72% males and 28% females; mean age of 69.96 ± 11.74 years). The frequencies of two polymorphisms of the HER-2-gene -1985G>T and P1170A C>G were detected using the quantitative real-time polymerase chain reaction (qRT-PCR) restriction fragment length polymorphism (RFLP) assay. The study was conducted according to the Declaration of Helsinki, the protocol was reviewed and approved by the institutional Ethics committee and all patients provided written informed consent.
Results
We found statistically significant difference in the distribution of genetic mutation variants -1985G>T and P1170A C>G among the patients with lung adenocarcinoma compared to healthy subjects (p < 0.001). The -1985G>T and P1170A C>G allelic variants were not significantly expressed among the patient and control groups in overall subject (p = 0.874).
Conclusions
Our study indicates that the expressions of genetic variants -1985G>T and P1170A C>G is associated with higher risk of development of lung adenocarcinoma. There was no statistical difference among patient and control groups in overall subjects.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract